April 27, 2026
Whitepaper: Reactive Insulin Protocols are Exposing Hospitals to Avoidable CMS and Quality Risk
Sliding scale insulin was designed for simplicity – not for today’s regulatory and clinical demands.
Hospitals that continue to rely on SSI face well-documented challenges: higher mean blood glucose levels, increased glycemic variability, longer lengths of stay and inconsistent results across care teams. The American Diabetes Association Standards of Care in Diabetes 2024 advises against using sliding scale insulin as the sole method of inpatient insulin therapy.
Now the risk extends beyond clinical variability.
This year, CMS began requiring hospitals to report severe hypoglycemia and hyperglycemia through eCQMs under the Hospital Inpatient Quality Reporting Program. Reactive protocols that allow preventable glucose excursions may increase scrutiny and downstream financial and reputational consequences.
This report details how hospitals can move toward patient-specific insulin dosing supported by standardized protocols, multidisciplinary oversight and integrated clinical decision support.
Learnings from this report include:
- The evidence linking SSI to preventable glycemic events and longer stays,
- How Temple Health eliminated SSI as standard practice and improved care quality,
- The hidden staffing and financial costs of reactive insulin management, and
- Structured approaches hospitals are using to phase out SSI.
Click Here to Download Whitepaper